Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Level BiotechnologyROCO:3118 76 EV-to-FCF is 30.74 as of Jul. 21, 2026, which is 265% above its 10-year median of 8.42. GuruFocus rates ROCO:3118 with a GF Score™ of 76/100 and a GF Value™ of NT$35.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 338 Biotechnology companies, Level Biotechnology ranks worse than 67.75% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Level Biotechnology's Enterprise Value is NT$828.0 Mil.
Level Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$26.9 Mil. Therefore, Level Biotechnology's EV-to-FCF for today is 30.74.
The historical rank and industry rank for Level Biotechnology's EV-to-FCF or its related term are showing as below:
ROCO:3118'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.12 Med: 8.42 Max: 194.77
Current: 30.74
During the past 13 years, the highest EV-to-FCF of Level Biotechnology was 194.77. The lowest was -6.12. And the median was 8.42.
ROCO:3118's EV-to-FCF is ranked worse than 67.75% of 338
companies
in the Biotechnology industry
Industry Median: 15.02
vs ROCO:3118: 30.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Level Biotechnology's PE Ratio (TTM) for today is calculated as:
Level Biotechnology's share price for today is NT$31.75.
Level Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Level Biotechnology EV-to-FCF Related Terms
Level Biotechnology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Level Biotechnology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:3118 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Level Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Level Biotechnology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Level Biotechnology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Level Biotechnology's EV-to-FCF falls into.
Level Biotechnology's current Enterprise Value is NT$828.0 Mil.
Level Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$26.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Level Biotechnology (ROCO:3118) has a EV-to-FCF of 30.74 as of Jul. 21, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Level Biotechnology and its competitors. This is 265% above median its historical median of 8.42. According to the industry distribution chart, Level Biotechnology ranks #229 out of 338 companies in the Biotechnology industry, placing it in the top 67.8%.
Is Level Biotechnology's EV-to-FCF too high?
Level Biotechnology's current EV-to-FCF of 30.74 is 265% above median its 10-year median of 8.42. The Biotechnology industry median EV-to-FCF is 15.02. Level Biotechnology's value of 30.74 is 104.7% above this industry median. Based on the distribution chart, Level Biotechnology ranks #229 out of 338 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Level Biotechnology ranks #229 out of 338 companies for EV-to-FCF. This places Level Biotechnology in the lower half of its industry. The industry median EV-to-FCF is 15.02. Level Biotechnology's value of 30.74 is 104.7% above this benchmark. While the company's 10-year median is 8.42 vs. the industry median of 15.02, Level Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.02, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Level Biotechnology's current EV-to-FCF of 30.74 is 104.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Level Biotechnology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Biotechnology's current EV-to-FCF is 30.74, which is 265% above median its own 10-year median of 8.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$35.57, compared to a current price of NT$31.75 — trading 10.7% below its estimated fair value. The current EV-to-FCF is 30.74, which is 265% above median its 10-year median of 8.42 and 104.7% above the Biotechnology industry median of 15.02. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current EV-to-FCF is 30.74 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Level Biotechnology (ROCO:3118) Overvalued in 2026?
Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued.
The current stock price of NT$31.75 is trading 10.7% below its estimated GF Value™ of NT$35.57.
GuruFocus considers Level Biotechnology to be Modestly Undervalued.
Key valuation signals for ROCO:3118:
EV-to-FCF: 30.74 (265% above median its 10-year median of 8.42)
GF Value™: NT$35.57 vs. price of NT$31.75 (10.7% below fair value)
Industry Position: 104.7% above the Biotechnology median (#229 of 338)
No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score
Get the complete analysis for ROCO:3118
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:3118 has been successfully added to your 
